Cantor Fitzgerald Increases Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $740.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price raised by analysts at Cantor Fitzgerald from $678.00 to $740.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has an “overweight” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target suggests a potential upside of 13.14% from the stock’s current price.

A number of other equities analysts also recently commented on the company. UBS Group reiterated a “neutral” rating on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Wells Fargo & Company lowered shares of Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $580.00 price objective on the stock. in a report on Friday, August 1st. Truist Financial reduced their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating on the stock in a report on Monday, August 11th. Morgan Stanley reduced their price target on shares of Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating on the stock in a research note on Friday, October 10th. Finally, Jefferies Financial Group boosted their price target on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a “buy” rating in a research note on Wednesday, August 27th. Three analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $813.78.

Regeneron Pharmaceuticals Trading Up 0.2%

Shares of NASDAQ:REGN opened at $654.04 on Wednesday. Regeneron Pharmaceuticals has a 1 year low of $476.49 and a 1 year high of $883.15. The firm has a market capitalization of $69.32 billion, a price-to-earnings ratio of 15.66, a price-to-earnings-growth ratio of 2.03 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.72. The business’s 50 day moving average price is $580.56 and its 200-day moving average price is $564.66.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. During the same quarter last year, the firm posted $12.46 EPS. The business’s revenue was up .9% on a year-over-year basis. On average, equities research analysts forecast that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Activest Wealth Management grew its position in shares of Regeneron Pharmaceuticals by 110.5% during the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 21 shares during the last quarter. Costello Asset Management INC purchased a new position in Regeneron Pharmaceuticals in the 1st quarter valued at $27,000. Saudi Central Bank purchased a new position in Regeneron Pharmaceuticals in the 1st quarter valued at $27,000. Salomon & Ludwin LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at about $27,000. Finally, Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at about $31,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.